皮肌炎市场：按类型、治疗类型、分销渠道、地区 - 规模、份额、展望、机会分析，2022-2030 年

皮肌炎是一种罕见的肌肉发炎疾病。表现为对称性近端肌无力、皮疹、食管功能障碍、间质性肺病等宏观症状。皮肌炎与恶性肿瘤密切相关，尤其是在成人中。皮肌炎是一种全身性疾病，最常影响皮肤和肌肉，但也会影响关节、食道、肺和心臟（较少见）。皮肌炎表现为特征性皮肤表现和对称性近端骨骼肌无力。它还会影响其他器官系统，例如肺、心血管系统和消化系统。皮肌炎是由多种因素引起的，包括遗传因素、免疫因素、感染性疾病、药物以及辐射等环境因素。

皮肌炎分为成人皮肌炎、肌源性皮肌炎和幼年型皮肌炎三种类型。)分为三种皮肌炎。皮肌炎肌炎是一个术语，用于描述具有皮肌炎皮肤病学特征但无相关肌肉表现的患者。幼年（小儿）皮肌炎（JDMS）是皮肌炎（DM）的一种早发形式，是一种累及血管的全身性自身免疫性炎症性肌病，其特征是近端和对称性肌肉无力、觉醒时以皮肤损害和全身症状为特征。

市场动态

市场参与者参与了皮肌炎新疗法的开发，预计这将在预测期内推动市场增长。例如，2022 年 5 月，临床阶段生物技术公司 Kezar Life Sciences, Inc. 宣布了 zetomipzomib (KZR-616) 在皮肌炎 (DM) 和多发性肌炎 (PM) 患者中的 PRESIDIO 2 期临床试验。试验结果。 PRESIDIO 试验的结果显示，大多数 DM 和 PM 患者的总改善评分（TIS）都有临床意义的改善。

研究的主要特征

• 本报告深入分析了以 2021 年为基准年的预测期 (2022-2030) 的全球皮肌炎市场、市场规模和復合年增长率 (CAGR%)。
• 解释了不同细分市场的潜在创收机会，并描述了针对该市场的有吸引力的投资建议矩阵。
• 它还提供关键见解，例如市场驱动因素和製约因素、机会、新产品发布或批准、市场趋势、区域前景以及主要参与者采用的竞争战略。
• 根据公司亮点、按类型划分的投资组合、主要亮点、财务业绩和市场战略等参数，介绍全球皮肌炎市场主要参与者的概况。
• 本研究涵盖的主要公司包括 AstraZeneca Plc.、Bristol-Myers Squibb Company、Octapharma AG、Corbus Pharmaceuticals Holdings, Inc.、CSL Limited、Ermium Therapeutics、Kezar Life Sciences Inc.、Mallinckrodt Plc.、Neovacs、 Horizo□□n Therapeutics plc.和辉瑞公司。
• 这份报告中的见解将使营销人员和企业高管能够就未来的产品发布、类型升级、市场扩张和营销策略做出明智的决策。我猜。
• 《全球皮肌炎市场》报告面向该行业的各种利益相关者，包括投资者、供应商、产品製造商、分销商、新进入者和金融分析师。
• 利益相关者可以通过用于分析全球皮肌炎市场的各种战略矩阵来促进决策制定。

内容

第 1 章目的和先决条件

• 调查目的
• 先决条件
• 缩写说明

第二章市场展望

• 报告内容
  • 市场定义和范围
• 执行摘要
  • 市场概况：按类型分类
  • 市场概况：按治疗类型分类
  • 市场概况：按销售渠道
  • 市场概况：按地区
  • 市场机会地图

第 3 章全球皮肌炎市场洞察

• 司机
• 约束因素
• 市场机会
• 影响分析
• 管道分析
• 害虫分析
• 波特的五力分析
• 主要发展状况
• 监管情景
• 保险报销场景
• 合併/收购场景
• 品牌映射

第 4 章全球皮肌炎市场：冠状病毒 (COVID-19) 大流行的影响

• OVID-19 的流行病学
• 对供需的影响
• 对临床试验的影响

第 5 章全球皮肌炎市场类型，2017-2030

• 成人皮肌炎
• 皮肌炎肌炎
• 幼年（儿科）皮肌炎 (JDMS)

第 6 章全球皮肌炎市场：按治疗类型分类，2017-2030

• 抗炎药
• 免疫抑製剂
• 免疫球蛋白
• 其他（血浆置换、单克隆抗体等）

第 7 章。全球皮肌炎市场：按分销渠道，2017-2030

• 医院药房
• 零售药房
• 在线药店

第 8 章全球皮肌炎市场：按地区划分，2017-2030

• 北美
• 美国
• 加拿大
• 拉丁美洲
• 巴西
• 墨西哥
• 阿根廷
• 其他拉丁美洲地区
• 欧洲
• 德国
• 英国
• 法国
• 意大利
• 西班牙
• 俄罗斯
• 其他欧洲地区
• 亚太地区
• 中国
• 印度
• 日本
• 澳大利亚
• 韩国
• 东盟
• 其他亚太地区
• 中东
• 海湾合作委员会
• 以色列
• 其他中东地区
• 非洲
• 南非
• 中非
• 北非

第九章公司简介

• 阿斯利康公司
  • 公司亮点
  • 产品组合
  • 主要亮点
  • 财务业绩
  • 市场策略
• 百时美施贵宝公司
  • 公司简介
  • 产品组合
  • 主要亮点
  • 效果趋势
  • 市场策略
• Octapharma 公司
  • 公司简介
  • 产品组合
  • 主要亮点
  • 效果趋势
  • 市场策略
• Corvus Pharmaceuticals Holdings Inc.
  • 公司简介
  • 产品组合
  • 主要亮点
  • 效果趋势
  • 市场策略
• CSL 有限公司
  • 公司简介
  • 产品组合
  • 主要亮点
  • 效果趋势
  • 市场策略
• 铒疗法
  • 公司简介
  • 产品组合
  • 主要亮点
  • 效果趋势
  • 市场策略
• 凯撒生命科学有限公司
  • 公司简介
  • 产品组合
  • 主要亮点
  • 效果趋势
  • 市场策略
• 马林克罗特公司
  • 公司简介
  • 产品组合
  • 主要亮点
  • 效果趋势
  • 市场策略
• 新后卫
  • 公司简介
  • 产品组合
  • 主要亮点
  • 效果趋势
  • 市场策略
• Horizo□□n Therapeutics plc.
  • 公司简介
  • 产品组合
  • 主要亮点
  • 效果趋势
  • 市场策略
• 辉瑞日本公司
  • 公司简介
  • 产品组合
  • 主要亮点
  • 财务业绩
  • 市场策略

第 10 章

• 调查方法
• 关于出版商

Dermatomyositis is a rare condition that causes muscle inflammation. It presents with symmetric proximal muscle weakness, skin rash, and extra macular manifestations such as esophageal dysfunction and interstitial lung disease. Dermatomyositis is strongly associated with malignancy, especially in adults. Dermatomyositis is a systemic disorder that most frequently affects the skin and muscles but may also affect the joints, the esophagus, the lungs, and less commonly, the heart. Dermatomyositis presents with characteristic skin findings and symmetric proximal skeletal muscle weakness. It can also affect other organ systems such as the pulmonary, cardiovascular, and gastrointestinal systems. Various factors cause dermatomyositis such as genetic factors, immunologic factors, and environmental factors such as infections, drugs, and radiation.

Furthermore, there are three types of dermatomyositis namely, Adult Dermatomyositis, Dermatomyositis Sine Myositis, and Juvenile (Childhood) Dermatomyositis (JDMS). Dermatomyositis Sine Myositis is a term used to describe patients who are present with the dermatological features of dermatomyositis but an absence of associated muscle findings. Juvenile (childhood) dermatomyositis (JDMS) is an early onset form of dermatomyositis (DM), a systemic, autoimmune inflammatory muscle disorder with vasculopathy, characterized by proximal and symmetrical muscle weakness, evocative skin lesions, and systemic manifestations.

Market Dynamics

Market players are involved in the development of novel treatment for dermatomyositis which is expected to propel the market growth over the forecast period. For instance, in May 2022, Kezar Life Sciences, Inc., a clinical-stage biotechnology company, announced result from the PRESIDIO Phase 2 clinical trial of zetomipzomib (KZR-616) in patients with dermatomyositis (DM) and polymyositis (PM). The results of the PRESIDIO trial showed that most DM and PM patients saw clinically meaningful improvements in total improvement score (TIS).

Key features of the study:

• This report provides an in-depth analysis of the global dermatomyositis market, market size (US$ Million), and compound annual growth rate (CAGR %) for the forecast period (2022-2030), considering 2021 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global dermatomyositis market based on the following parameters - company highlights, types portfolio, key highlights, financial performance, and market strategies
• Key companies covered as a part of this study include AstraZeneca Plc., Bristol-Myers Squibb Company, Octapharma AG, Corbus Pharmaceuticals Holdings, Inc., CSL Limited, Ermium Therapeutics, Kezar Life Sciences Inc., Mallinckrodt Plc., Neovacs, Horizon Therapeutics plc., and Pfizer Inc.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• The global dermatomyositis market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global dermatomyositis market

Detailed Segmentation:

• Global Dermatomyositis Market, By Type:
  • Adult Dermatomyositis
  • Dermatomyositis Sine Myositis
  • Juvenile (Childhood) Dermatomyositis (JDMS)
• Global Dermatomyositis Market, By Treatment Type:
  • Anti-inflammatory Medication
  • Immunosuppressive Drugs
  • Immunoglobulin
  • Others (Plasma Exchange, Monoclonal antibody among others)
• Global Dermatomyositis Market, By Distribution Channel:
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• Global Dermatomyositis Market, By Region:
  • North America
    • By Country
  • U.S.
  • Canada
  • Latin America
    • By Country
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
  • Europe
    • By Country
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe
  • Asia Pacific
    • By Country
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • ASEAN
  • Rest of Asia Pacific
  • Middle East
    • By Country
  • GCC
  • Israel
  • Rest of Middle East
  • Africa
    • By Country/Region
  • South Africa
  • Central Africa
  • North Africa
• Company Profiles
  • AstraZeneca Plc.
    • Company Highlights
    • Products Portfolio
    • Key Highlights
    • Financial Performance
    • Strategies
  • Bristol-Myers Squibb Company
  • Octapharma AG
  • Corbus Pharmaceuticals Holdings, Inc.
  • CSL Limited
  • Ermium Therapeutics
  • Kezar Life Sciences Inc.
  • Mallinckrodt Plc.
  • Neovacs, Horizon Therapeutics plc.
  • Pfizer Inc.

"*" marked represents similar segmentation in other categories in the respective section.

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Market Snapshot, By Type
  • Market Snapshot, By Treatment Type
  • Market Snapshot, By Distribution Channel
  • Market Snapshot, By Region
  • Market Opportunity Map

3. Global Dermatomyositis Market Insights

• Drivers
• Restraints
• Opportunity
• Impact Analysis
• Pipeline Analysis
• PEST Analysis
• Porter's Five Forces Analysis
• Key Developments
• Regulatory Scenario
• Reimbursement Scenario
• Merger & Acquisition Scenario
• Brand Mapping

4. Global Dermatomyositis Market - Impact of Coronavirus (Covid-19) Pandemic

• OVID-19 Epidemiology
• Impact On Supply And Demand
• Impact on Clinical Trials

5. Global Dermatomyositis Market, By Type, 2017 - 2030 (US$ Million)

• Introduction
  • Market Share Analysis, 2022 and 2030 (%)
  • Y-o-Y Growth Analysis, 2017 - 2030
  • Segment Trends
• Adult Dermatomyositis
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030 (US$ Million)
• Dermatomyositis Sine Myositis
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030 (US$ Million)
• Juvenile (Childhood) Dermatomyositis (JDMS)
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030 (US$ Million)

6. Global Dermatomyositis Market, By Treatment Type, 2017 - 2030 (US$ Million)

• Introduction
  • Market Share Analysis, 2022 and 2030 (%)
  • Y-o-Y Growth Analysis, 2017 - 2030
  • Segment Trends
• Anti-inflammatory Medication
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030 (US$ Million)
• Immunosuppressive Drugs
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030 (US$ Million)
• Immunoglobulin
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030 (US$ Million)
• Others (Plasma Exchange, Monoclonal antibody among others)
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030 (US$ Million)

7. Global Dermatomyositis Market, By Distribution Channel, 2017 - 2030 (US$ Million)

• Introduction
  • Market Share Analysis, 2022 and 2030 (%)
  • Y-o-Y Growth Analysis, 2017 - 2030
  • Segment Trends
• Hospital Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030 (US$ Million)
• Retail Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030 (US$ Million
• Online Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030 (US$ Million)

8. Global Dermatomyositis Market, By Region, 2017 - 2030 (US$ Million)

• Introduction
  • Market Share Analysis, 2022 and 2030 (%)
  • Y-o-Y Growth Analysis, 2017 - 2030
  • Region at Trends
• North America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Type, 2017 - 2030, (US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2017 - 2030, (US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017-2030, (US$ Mn)
  • Market Size and Forecast By Value, and Y-o-Y Growth, By Country, 2017-2030, (US$ Million)
• U.S.
• Canada
• Latin America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Type, 2017 - 2030, (US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2017 - 2030, (US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017-2030, (US$ Mn)
  • Market Size and Forecast By Value, and Y-o-Y Growth, By Country, 2017-2030, (US$ Million)
• Brazil
• Mexico
• Argentina
• Rest of Latin America
• Europe
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Type, 2017 - 2030, (US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2017 - 2030, (US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017-2030, (US$ Mn)
  • Market Size and Forecast By Value, and Y-o-Y Growth, By Country, 2017-2030, (US$ Million)
• Germany
• U.K.
• France
• Italy
• Spain
• Russia
• Rest of Europe
• Asia Pacific
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Type, 2017 - 2030, (US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2017 - 2030, (US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017-2030, (US$ Mn)
  • Market Size and Forecast By Value, and Y-o-Y Growth, By Country, 2017-2030, (US$ Million)
• China
• India
• Japan
• Australia
• South Korea
• ASEAN
• Rest of Asia Pacific
• Middle East
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Type, 2017 - 2030, (US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2017 - 2030, (US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017-2030, (US$ Mn)
  • Market Size and Forecast By Value, and Y-o-Y Growth, By Country, 2017-2030, (US$ Million)
• GCC
• Israel
• Rest of Middle East
• Africa
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Type, 2017 - 2030, (US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2017 - 2030, (US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017-2030, (US$ Mn)
  • Market Size and Forecast By Value, and Y-o-Y Growth, By Country/Region, 2017-2030, (US$ Million)
• South Africa
• Central Africa
• North Africa

9. Company Profiles

• AstraZeneca Plc.*
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Bristol-Myers Squibb Company
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Octapharma AG
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Corbus Pharmaceuticals Holdings, Inc.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• CSL Limited
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Ermium Therapeutics
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Kezar Life Sciences Inc.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Mallinckrodt Plc.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Neovacs
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Horizon Therapeutics plc.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Pfizer Inc.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies

10. Section

• Research Methodology
• About us